- AngioDynamics is in a "prove it" phase, now having to plea their case in the investment debate through performance this year.
- We would note that several COVID-related headwinds remain, and management sees a 10-15% COVID-19 headwind to total sales this year.
- We feel the cash position is tight, and several data points evidence this based on horizontal and vertical movement through the financial statements.
- The valuation is not attractive at current levels, and we feel shares are worth ~$10 right now.
- Here we cover all of the moving parts required in one's investment reasoning to guide the investment debate.
For further details see:
AngioDynamics: Cash Position Is Tight, It's Prove It Time In The Investment Debate